09R
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The compan… Read more
09R (09R) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.407x
Based on the latest financial reports, 09R (09R) has a cash flow conversion efficiency ratio of -0.407x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-13.36 Million) by net assets (€32.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
09R - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how 09R's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
09R Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 09R ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intelligent Protection Management Corp
NASDAQ:IPM
|
0.007x |
|
Appia Energy Corp
OTCQB:APAAF
|
0.015x |
|
Aether Holdings, Inc.
NASDAQ:ATHR
|
-0.299x |
|
CLPS INC. DL-0001
F:1UK
|
N/A |
|
Long An Food Processing Export JSC
VN:LAF
|
N/A |
|
Gopeng Bhd
KLSE:2135
|
0.016x |
|
Nigbas Nigde Beton Sanayi ve Ticaret AS
IS:NIBAS
|
-0.054x |
|
Eastern Commercial Leasing Public Company Limited
BK:ECL
|
0.103x |
Annual Cash Flow Conversion Efficiency for 09R (2021–2024)
The table below shows the annual cash flow conversion efficiency of 09R from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €68.15 Million | €-25.24 Million | -0.370x | -105.66% |
| 2023-12-31 | €-2.13 Million | €-13.95 Million | 6.545x | +54.48% |
| 2022-12-31 | €-3.01 Million | €-12.74 Million | 4.237x | +483.70% |
| 2021-12-31 | €5.86 Million | €-6.47 Million | -1.104x | -- |